Verastem price target lowered to $18 from $19 at BTIG

BTIG lowered the firm’s price target on Verastem (VSTM) to $18 from $19 and keeps a Buy rating on the shares after its Q1 results. The revamped commercial efforts should get the company back on track with long-term peak sales potential in LGSOC – Low-Grade Serous Ovarian Cancer – remaining intact, the analyst tells investors in a research note.